This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
A comprehensive evaluation of commonly used clinical neuroprotective drugs was conducted, analyzing their practical application value in acute ischemic stroke treatment across six dimensions: safety, efficacy, cost-effectiveness, innovation, appropriateness, and accessibility. In a real-world clinical setting, this prospective observational study design primarily evaluates the association between edaravone and dexrazoxane usage and the efficacy and safety outcomes in patients with mild-to-moderate ischemic stroke, while conducting subgroup analyses based on different Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classifications.
Study Type
OBSERVATIONAL
Enrollment
600
Proportion of patients with Modified Rankin Scale（mRS ）scores of 0-1
Time frame: 90 days
Proportion of patients with mRS scores of 0-2
Time frame: 30 days
Percentage reduction in National Institutes of Health Stroke Scale （NIHSS ）score compared to pre-treatment
Time frame: 90 days after medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.